SCHEMBL70442

SCHEMBL70442

COCCC1CN(C(c2ccccc2)c2ccccc2)C1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
OPRM1 P35372 4/20 0.42
CYP2D6 P10635 3/20 0.42
CHRM2 P08172 1/20 0.42
CHRM4 P08173 1/20 0.42
CHRM5 P08912 1/20 0.42
ADRA2A P08913 1/20 0.42
ADORA3 P0DMS8 1/20 0.42
CHRM1 P11229 1/20 0.42
CHRM3 P20309 1/20 0.42
DRD1 P21728 1/20 0.42
ADRA1D P25100 1/20 0.42
HTR2A P28223 1/20 0.42
HTR2C P28335 1/20 0.42
HRH1 P35367 1/20 0.42
DRD3 P35462 1/20 0.42
HTR2B P41595 1/20 0.42
SLC6A3 Q01959 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL85215 0.83 OPRM1 (0.44) OPRM1CYP2D6CHRM2CHRM4CHRM5
SCHEMBL14491539 0.81 DPP4 (0.50) ALDH1A1OPRM1CYP2D6CHRM2CHRM4
SCHEMBL1768990 0.79 ALDH1A1 (0.41) KDM4EALDH1A1SMN1; SMN2OPRM1CYP2D6
SCHEMBL13596965 0.79 DPP4 (0.58) ALDH1A1OPRM1CYP2D6CHRM2CHRM4
SCHEMBL71274 0.78 SLC6A9 (0.43) ALDH1A1OPRM1CYP2D6CHRM2CHRM4
SCHEMBL5969007 0.78 HRH1 (0.44) OPRM1CYP2D6CHRM2CHRM4CHRM5
SCHEMBL85392 0.78 OPRM1 (0.48) ALDH1A1OPRM1CYP2D6CHRM2CHRM4
SCHEMBL1769117 0.77 ALDH1A1 (0.40) KDM4EALDH1A1SMN1; SMN2OPRM1CYP2D6
SCHEMBL14839600 0.76 ALDH1A1 (0.39) KDM4EALDH1A1SMN1; SMN2OPRM1CYP2D6
SCHEMBL7817761 0.76 SLC6A3 (0.40) KDM4EALDH1A1SMN1; SMN2OPRM1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1961750-B1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO CO LTD (JP) 2013-09-18 EP disclosed
US-20130065882-A1 VLA-4 inhibitory drug MACHINAGA NOBUO (JP) 2013-03-14 US disclosed
US-20120157437-A1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-06-21 US disclosed
US-8129366-B2 VLA-4 inhibitory drug DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-03-06 US disclosed
US-20090233901-A1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-17 US disclosed
EP-1961750-A1 VLA-4 INHIBITORY DRUG Daiichi Sankyo Company, Limited (JP) 2008-08-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157437-A1 VLA-4 INHIBITORY DRUG VCAM1, ITGB4, ITGA4 KDM4E 983/4885ALDH1A1 216/4885SMN1; SMN2 4739/4885
US-20130065882-A1 VLA-4 inhibitory drug VCAM1, ITGB4, ITGA4 KDM4E 996/4885ALDH1A1 207/4885SMN1; SMN2 4702/4885
US-20090233901-A1 VLA-4 INHIBITORY DRUG VCAM1, ITGB4, ITGA4 KDM4E 1607/4885ALDH1A1 525/4885SMN1; SMN2 4787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.